MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-30-2026
Akari Therapeutics, Plc ROA Ratio 2011-2026 | AKTX
Annual ROA Ratio Akari Therapeutics, Plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -36.12 | -39.14 | -229.8 | -173.83 | -149.59 | -116.96 | -247.67 | -205.08 | -121.86 | -39.55 | -64.84 | -148.89 | -46.22 | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -36.12 | -247.67 | -124.58 |
Quarterly ROA Ratio Akari Therapeutics, Plc
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -130.99 | -222.77 | -367.94 | -455.58 | -455.58 | -349.69 | -200.79 | - | - | - | - | - | - | -89.99 | -179.99 | -179.99 | -83.32 | -76.65 | -38.14 | -83.5 | -111.57 | -146.3 | -223.78 | -159.29 | -159.29 | -178.08 | -95.99 | -93.72 | -46.86 | -47.86 | -2.0 | -2.0 | -1.0 | -12.19 | -22.39 | -27.13 | -77.49 | -139.05 | -173.15 | -109.28 | -115.85 | -60.87 | -49.97 | -189.86 | -189.86 | -183.29 | -148.89 | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -1.0 | -455.58 | -138.58 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aquestive Therapeutics
AQST
|
-52.23 | $ 4.12 | -0.36 % | $ 441 M |  USA |
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
Arcturus Therapeutics Holdings
ARCT
|
-24.26 | $ 8.32 | 3.67 % | $ 228 M |  Israel |
 |
Arcutis Biotherapeutics
ARQT
|
-3.73 | $ 23.65 | 0.08 % | $ 3.01 B | USA |
 |
BioVie
BIVI
|
-81.36 | $ 1.46 | 2.82 % | $ 2.16 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-33.24 | $ 2.32 | 4.98 % | $ 908 M | Israel |
 |
BioNTech SE
BNTX
|
65.02 | $ 91.44 | 0.29 % | $ 27.2 B | Germany |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
23.87 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M | France |
 |
BioXcel Therapeutics
BTAI
|
-155.62 | $ 1.16 | -2.12 % | $ 14.2 M | USA |
 |
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Burford Capital Limited
BUR
|
5.51 | $ 4.52 | 9.18 % | $ 683 M | Britain |
 |
Acorda Therapeutics
ACOR
|
-232.99 | - | -24.86 % | $ 820 K | USA |
 |
Cabaletta Bio
CABA
|
-101.68 | $ 3.1 | 4.56 % | $ 311 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-72.8 | - | - | $ 86.2 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-86.4 | $ 3.17 | 1.44 % | $ 6.9 B | Israel |
 |
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Applied Molecular Transport
AMTI
|
-117.57 | - | - | $ 10.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-275.96 | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
-19.87 | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | USA |
 |
Catalyst Biosciences
CBIO
|
5.95 | $ 19.48 | 0.39 % | $ 1.74 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Allena Pharmaceuticals
ALNA
|
-140.01 | - | 3.16 % | $ 1.9 M | USA |
 |
Codexis
CDXS
|
-29.75 | $ 1.95 | 6.87 % | $ 170 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-20.15 | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-206.44 | - | 10.36 % | $ 9.8 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
-44.67 | $ 3.01 | 0.67 % | $ 257 M | USA |
 |
Cerus Corporation
CERS
|
-7.04 | $ 1.91 | 2.69 % | $ 364 M | USA |
 |
Cullinan Management
CGEM
|
-49.04 | $ 15.11 | 4.71 % | $ 910 M | USA |
 |
Coherus BioSciences
CHRS
|
65.04 | $ 1.72 | -0.87 % | $ 201 M | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-88.77 | $ 0.46 | -13.02 % | $ 5.27 M | Israel |
 |
Aravive
ARAV
|
-122.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Aptose Biosciences
APTO
|
-254.37 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-97.25 | - | -39.0 % | $ 4.57 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
-183.81 | $ 2.25 | -0.44 % | $ 998 K | USA |
 |
CureVac N.V.
CVAC
|
-35.55 | - | - | $ 867 M | Germany |
 |
AstraZeneca PLC
AZN
|
0.11 | - | - | $ 96.9 B | Britain |
 |
Catalyst Pharmaceuticals
CPRX
|
19.41 | $ 24.95 | 1.05 % | $ 3.05 B | USA |
 |
Celldex Therapeutics
CLDX
|
-44.38 | $ 31.33 | 0.85 % | $ 2.08 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-46.69 | $ 10.27 | 0.98 % | $ 137 M | USA |
 |
Cardiff Oncology
CRDF
|
-74.09 | $ 1.6 | 1.27 % | $ 107 M | USA |
 |
Avenue Therapeutics
ATXI
|
-99.25 | - | -52.27 % | $ 4.45 M | USA |